Response to initial therapy
| Treatment . | n . | CR, n (%) . | Nodular PR/unconfirmed CR, n (%) . | PR, n (%) . | Objective response, n (%) . |
|---|---|---|---|---|---|
| Purine analogue and rituximab (FCR-like) regimens* | 25 | 7 (28), 7 of 7 flow negative | 3 (12) | 8 (32) | 18 (72) |
| FCR + alemtuzumab (CFAR) | 16 | 7 (44), 5 of 6 flow negative | 1 (6) | 5 (31) | 13 (81) |
| Rituximab without chemotherapy† | 6 | 1 (17), 1 of 1 flow negative | 1 (17) | 1 (17) | 3 (50) |
| Alkylator-based regimens‡ | 4 | 0 | 0 | 1 (25) | 1 (25) |
| Lenalidomide | 4 | 0 | 0 | 1 (25) | 1 (25) |
| Treatment . | n . | CR, n (%) . | Nodular PR/unconfirmed CR, n (%) . | PR, n (%) . | Objective response, n (%) . |
|---|---|---|---|---|---|
| Purine analogue and rituximab (FCR-like) regimens* | 25 | 7 (28), 7 of 7 flow negative | 3 (12) | 8 (32) | 18 (72) |
| FCR + alemtuzumab (CFAR) | 16 | 7 (44), 5 of 6 flow negative | 1 (6) | 5 (31) | 13 (81) |
| Rituximab without chemotherapy† | 6 | 1 (17), 1 of 1 flow negative | 1 (17) | 1 (17) | 3 (50) |
| Alkylator-based regimens‡ | 4 | 0 | 0 | 1 (25) | 1 (25) |
| Lenalidomide | 4 | 0 | 0 | 1 (25) | 1 (25) |
CR indicates complete response; PR, partial response; FCR, fludarabine, cyclophosphamide, plus rituximab; flow negative, < 17 cos/19 cells in lymxxxx rate; GM-CSF, granulocyte macrophage colony-stimulating factor; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; and R-CVP, rituximab plus cyclophosphamide, vincristine, and prednisone.
FCR (19); FCR & mitoxantrone (2); fludarabine & rituximab (1); pentostatin & rituximab (1); and pentostatin, cyclophosphamide & rituximab (2).
Rituximab (1); rituximab + GM-CSF (4); and rituximab + methylprednisolone (1).
R-CHOP (2); R-CVP (1); and chlorambucil (1).